Janux Therapeutics, Inc. (JANX)
Nasdaq · Pharmaceutical Preparations · Manufacturing · CIK 1817713 · fiscal year ends in Dec
Closing price $17.85 on 29 Oct 2026; 52-week range $12.18 to $34.74.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Revenue, last twelve months
- $24.0M
- Revenue growth
- 5367.0%
- Net income, last twelve months
- -$102.6M
- Earnings per share
- -$1.64
- Operating margin
- -598.1%
- Net margin
- -427.5%
- Free cash flow
- -$41.9M
- Return on equity
- -11.1%
- Market value
- $1.1B
- Cash
- $27.8M
- Debt
- $0
- Debt to equity
- 0.00
- Shares outstanding
- 61.1M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | 31 Dec 2025 | $10.0M | -$157.7M | -$113.6M | -$1.83 | -$83.3M | 10-K filed 26 Feb 2026 |
| FY2024 | 31 Dec 2024 | $10.6M | -$98.8M | -$69.0M | -$1.28 | -$44.2M | 10-K filed 27 Feb 2025 |
| FY2023 | 31 Dec 2023 | $8.1M | -$73.0M | -$58.3M | -$1.32 | -$52.4M | 10-K filed 8 Mar 2024 |
| FY2022 | 31 Dec 2022 | $8.6M | -$67.1M | -$63.1M | -$1.52 | -$49.4M | 10-K filed 10 Mar 2023 |
| FY2021 | 31 Dec 2021 | $3.6M | -$32.9M | -$32.7M | -$1.39 | -$18.5M | 10-K filed 18 Mar 2022 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | 30 Jun 2026 | $10.3M | -$22.0M | -$0.35 |
| Q1 FY2026 | 31 Mar 2026 | $3.7M | -$24.4M | -$0.39 |
| Q4 FY2025 | 31 Dec 2025 | $0 | -$31.9M | -$0.51 |
| Q3 FY2025 | 30 Sep 2025 | $10.0M | -$24.3M | -$0.39 |
| Q2 FY2025 | 30 Jun 2025 | $0 | -$33.9M | -$0.55 |
| Q1 FY2025 | 31 Mar 2025 | $0 | -$23.5M | -$0.38 |
| Q4 FY2024 | 31 Dec 2024 | $0 | -$20.2M | -$0.36 |
| Q3 FY2024 | 30 Sep 2024 | $439.0K | -$28.1M | -$0.51 |
Company events
The newest 8-K filings of 49 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 6 Aug 2026 | 8-K | Results | 2.02, 9.01 |
| 23 Jun 2026 | 8-K | Other events | 8.01 |
| 12 Jun 2026 | 8-K | Shareholder vote | 5.07 |
| 7 May 2026 | 8-K | Results | 2.02, 9.01 |
| 28 Apr 2026 | 8-K | Leadership change | 5.02 |
| 26 Feb 2026 | 8-K | Results | 2.02, 9.01 |
| 22 Jan 2026 | 8-K | Material agreement, Investor update | 1.01, 7.01, 9.01 |
| 6 Nov 2025 | 8-K | Results | 2.02, 9.01 |
| 19 Sep 2025 | 8-K | Leadership change | 5.02 |
| 7 Aug 2025 | 8-K | Results | 2.02, 9.01 |
| 13 Jun 2025 | 8-K | Shareholder vote | 5.07 |
| 8 May 2025 | 8-K | Results | 2.02, 9.01 |
Every filing
The newest filings with the SEC of 115 held.
| Filed | Form | Period |
|---|---|---|
| 6 Aug 2026 | 10-Q | 30 Jun 2026 |
| 6 Aug 2026 | 8-K | 6 Aug 2026 |
| 23 Jun 2026 | 8-K | 23 Jun 2026 |
| 12 Jun 2026 | 8-K | 11 Jun 2026 |
| 7 May 2026 | 10-Q | 31 Mar 2026 |
| 7 May 2026 | 8-K | 7 May 2026 |
| 28 Apr 2026 | 8-K | 28 Apr 2026 |
| 28 Apr 2026 | ARS | 31 Dec 2025 |
| 28 Apr 2026 | DEFA14A | – |
| 28 Apr 2026 | DEF 14A | 11 Jun 2026 |
| 26 Feb 2026 | S-8 | – |
| 26 Feb 2026 | 10-K | 31 Dec 2025 |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months.
| Traded | Insider | Type | Shares | Price | Value | Held after | Form 4 |
|---|---|---|---|---|---|---|---|
| 2 Jun 2026 | Doyle Janeen Noel, Chief Corp. & Bus. Dev. Ofcr | Sale outside a trading plan | 4,059 | $14.03 | $56.9K | 75,941 | 4 Jun 2026 |
| 11 May 2026 | Dobek Maria, Vice President, Accounting | Sale outside a trading plan | 2,038 | $14.17 | $28.9K | 32,270 | 13 May 2026 |
| 2 Jan 2026 | Meyer Andrew Hollman, Chief Business Officer | Sale outside a trading plan | 1,879 | $13.73 | $25.8K | 83,095 | 2 Jan 2026 |
| 2 Jan 2026 | Diraimondo Thomas, Chief Scientific Officer | Sale outside a trading plan | 2,505 | $13.73 | $34.4K | 124,425 | 2 Jan 2026 |
| 2 Jan 2026 | Campbell David Alan, President and CEO | Sale outside a trading plan | 8,072 | $13.73 | $110.8K | 284,982 | 2 Jan 2026 |
| 2 Jan 2026 | Winter Charles M., Chief Technical Officer | Sale outside a trading plan | 2,401 | $13.73 | $33.0K | 77,721 | 2 Jan 2026 |
| 2 Jan 2026 | Mciver Zachariah, Chief Medical Officer | Sale outside a trading plan | 2,714 | $13.73 | $37.3K | 23,286 | 2 Jan 2026 |
| 2 Jan 2026 | Dobek Maria, Vice President, Accounting | Sale outside a trading plan | 1,462 | $13.73 | $20.1K | 15,373 | 2 Jan 2026 |
| 1 Dec 2025 | Meyer Andrew Hollman, Chief Business Officer | Sale under a trading plan | 2,700 | $32.85 | $88.7K | 85,607 | 3 Dec 2025 |
| 1 Dec 2025 | Meyer Andrew Hollman, Chief Business Officer | Sale under a trading plan | 633 | $33.52 | $21.2K | 84,974 | 3 Dec 2025 |
| 14 Nov 2025 | Meyer Andrew Hollman, Chief Business Officer | Sale under a trading plan | 3,333 | $30.00 | $100.0K | 84,974 | 14 Nov 2025 |
| 28 Oct 2025 | Meyer Andrew Hollman, Chief Business Officer | Sale under a trading plan | 16,665 | $30.06 | $501.0K | 82,139 | 30 Oct 2025 |
Planned insider sales
Form 144 notices, filed when the sell order goes to the broker.
| Filed | Seller | Shares | Value | Planned sale |
|---|---|---|---|---|
| 2 Jun 2026 | Janeen Noel Doyle, Officer | 4,059 | $56.9K | 2 Jun 2026 |
| 13 Apr 2026 | ANDY MEYER, Former Affiliate | 1,877 | $28.2K | 13 Apr 2026 |
| 2 Apr 2026 | ZACHARIAH A MCIVER, Former Officer | 74,802 | $1.1M | 2 Apr 2026 |
| 26 Jan 2026 | ANDY MEYER, Former Affiliate | 178,767 | $2.6M | 26 Jan 2026 |
| 23 Jan 2026 | ANDY MEYER, Former Affiliate | 118,122 | $1.7M | 23 Jan 2026 |
| 15 Dec 2025 | BYRON C ROBINSON, Officer | 16,666 | $258.4K | 15 Dec 2025 |
| 8 Dec 2025 | BYRON C ROBINSON, Officer | 50,000 | $826.0K | 8 Dec 2025 |
| 2 Dec 2025 | BYRON C ROBINSON, Officer | 63,125 | $1.0M | 2 Dec 2025 |
| 1 Dec 2025 | ANDREW MEYER, Officer | 3,333 | $113.6K | 1 Dec 2025 |
| 14 Nov 2025 | ANDREW MEYER, Officer | 3,333 | $91.5K | 14 Nov 2025 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 14 Aug 2026 | Point72 Asset Management, L.P. | 13G amended | 3.3% | 2.0M |
| 13 Aug 2026 | JANUS HENDERSON GROUP Ltd. | 13G amended | 0.3% | 172.2K |
| 28 Jul 2026 | BlackRock, Inc. | 13G amended | 6.7% | 4.1M |
| 15 May 2026 | JANUS HENDERSON GROUP PLC | 13G amended | 6.9% | 4.2M |
| 12 May 2026 | STATE STREET CORPORATION | 13G | 4.1% | 2.5M |
| 6 May 2026 | FMR LLC | 13G amended | 4.2% | 2.5M |
| 29 Apr 2026 | Point72 Asset Management, L.P. | 13G | 5% | 3.1M |
| 29 Apr 2026 | Point72 Asset Management, L.P. | 13G | 5% | 3.1M |
| 17 Feb 2026 | JANUS HENDERSON GROUP PLC | 13G amended | 8.9% | 5.4M |
| 9 Feb 2026 | STATE STREET CORPORATION | 13G | 6.4% | 3.9M |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 5.3M | -6.28% | 6.2 |
| 30 Sep 2026 | 5.7M | -3.52% | 5.86 |
| 15 Sep 2026 | 5.9M | -2.83% | 5.89 |
| 31 Aug 2026 | 6.1M | -8.5% | 7.81 |
| 14 Aug 2026 | 6.6M | +11.88% | 10.9 |
| 31 Jul 2026 | 5.9M | -8.23% | 7.74 |
| 15 Jul 2026 | 6.5M | -9.2% | 6.43 |
| 30 Jun 2026 | 7.1M | -6.66% | 3.59 |
Funds that hold it
From each fund's latest Form 13F.
228 funds held it at 30 Jun 2026: 118 added and 45 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| Ra Capital Management, L.P. | 11,189,693 | $171.9M | 0 |
| BlackRock, Inc. | 6,134,667 | $94.2M | +701,434 |
| Prosight Management, LP | 3,804,481 | $58.4M | +254,481 |
| State Street Corp. | 3,004,899 | $46.2M | +540,882 |
| FMR LLC | 2,412,825 | $37.1M | -122,899 |
| Federated Hermes, Inc. | 2,352,927 | $36.1M | +2,298,727 |
| Point72 Asset Management, L.P. | 1,993,837 | $30.6M | +837,697 |
| Vanguard Capital Management LLC | 1,857,351 | $28.5M | +45,986 |
| TCG Crossover Management, LLC | 1,789,617 | $27.5M | 0 |
| Alyeska Investment Group, L.P. | 1,647,140 | $25.3M | +46,051 |
Peers
Companies in the same industry.
- Eli Lilly & Co. (LLY): revenue $86.5B, market value $1.29T
- Johnson & Johnson (JNJ): revenue $99.3B, market value $662.4B
- AbbVie Inc. (ABBV): revenue $64.4B, market value $513.9B
- Merck & Co., Inc. (MRK): revenue $66.6B, market value $361.0B
- Novartis AG (NVS): revenue $54.5B, market value $307.3B
- AstraZeneca PLC (AZN): revenue $58.7B, market value $270.6B
- Abbott Laboratories (ABT): revenue $46.6B, market value $180.9B
- Novo Nordisk A/S (NVO): revenue $46.8B, market value $174.8B
- Pfizer Inc. (PFE): revenue $63.7B, market value $170.7B
- Vertex Pharmaceuticals Inc. (VRTX): revenue $12.6B, market value $136.8B